Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
|Videos|May 9, 2014
Dutasteride for the Treatment of Prostate Cancer
Author(s)Rana R. McKay, MD
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
Advertisement
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
- Dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT. It is classically used for people with benign prostatic hypertrophy.
- In a phase II trial, dutasteride was combined with abiraterone acetate for the treatment of metastatic castration resistant prostate cancer.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5